Seminal Contributions
SLICC has made several seminal contributions:
- 1. Development of the SLICC/American College of Rheumatology (ACR) Damage Index (SDI) in 1996 (led by Dr. Gladman)
- 2. Development of the SLICC Classification Criteria for Systemic Lupus Erythematosus in 2012 (led by Dr. Petri)
- 3. Creating a definition of Systemic Lupus Erythematosus disease flare (led by Dr. Isenberg)
Ongoing Research
Currently, SLICC members are engaged in several ongoing areas of key focus:
- 1. Longitudinal follow up of the Inception Cohort regarding the outcomes of atherosclerosis, nervous system involvement and metabolic involvement (led by Drs. Urowitz, Hanly, and Bruce)
- 2. Development of models based on analysis of longitudinal data from the Inception Cohort, which describe likelihood of developing lupus nephritis and end-stage renal disease as well as other organ-related damage accrual (led by Drs. Hanly, Farewell, and Bruce)
- 3. Evaluation of the association between glucocorticoid usage and damage accrual (led by Drs. Bruce and Mak)
- 4. Economic analysis of long-term costs associated with renal involvement, damage accrual, and transitions between disease activity states using the Inception Cohort (led by Dr. Clarke)
- 5. Evaluating the risk and determinants of malignancy in patients with lupus using the prevalent cohorts at each SLICC site (led by Drs. Bernatsky, Ramsey-Goldman, and Clarke)
Novel Initiatives
SLICC is engaged in several novel initiatives:
- 1. Development of a pregnancy cohort (led by Drs. Vinet, Bernatsky, and Buyon)
- 2. Adverse pregnancy outcomes and risk of cardiovascular disease in SLE (led by Drs. Jacobsen and Vinet)
- 3. Development of a working group on microparticles in SLE (led by Drs. Fortin and Boilard)
- 4. Revision of the SDI (led by Drs. Bruce, Inanc, and Petri)